Company intelligence / Profile preview

GenKOre

Daejeon, South Korea

Ownership: Private
Development stage: Other

Overview

GenKOre is developing in vivo gene-editing therapies using its proprietary hypercompact CRISPR-Cas12f platform called TaRGET, which allows entire editing modules to be delivered using a single AAV vector. The company is currently in preclinical stage with collaborative research programs for ocular diseases.[2]

Therapeutic areas: NeurologyOphthalmologyRare Diseases
Modalities: Gene therapyCRISPR-based therapy
Industry: Biotech

Partnerships

RevvityUS-based biotech company

Beyond the preview

Go deeper on GenKOre.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenKOre.

Explore the full profile